Axsome Therapeutics: A High-Flying Stock with More Upside Ahead

Axsome Therapeutics has seen significant growth over the past five years due to clinical and regulatory progress. The company's current lineup includes Auvelity, Sunosi, and Symbravo, with revenue growing 63% YoY in Q3. Axsome is seeking new approvals and label expansions, including a potential indication for Auvelity in Alzheimer's disease agitation. The company is also working on several other products, such as AXS-12 for cataplexy and AXS-14 for fibromyalgia, which could add billions to its sales potential.